Smith & Nephew’s (SN) Hold Rating Reiterated at Berenberg Bank

Berenberg Bank reissued their hold rating on shares of Smith & Nephew (LON:SN) in a report published on Friday morning, MarketBeat.com reports. Berenberg Bank currently has a GBX 1,300 price objective on the stock.

Other analysts have also issued reports about the stock. Citigroup increased their price target on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research report on Friday, October 31st. Panmure Gordon reissued a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a research report on Tuesday, December 9th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Finally, Royal Bank Of Canada lowered Smith & Nephew to a “sector perform” rating and decreased their price objective for the company from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Smith & Nephew has a consensus rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Trading Down 0.8%

Shares of LON SN opened at GBX 1,225.50 on Friday. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The company has a 50 day simple moving average of GBX 1,235.01 and a 200-day simple moving average of GBX 1,285.65. The firm has a market cap of £13.43 billion, a PE ratio of 44.12, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insider Activity

In other news, insider Deepak Nath sold 1,240 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total transaction of £15,586.80. Company insiders own 0.19% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.